Promising drug for immunotherapy side effects never tested: trial withdrawn
Disease control
Terminated
This phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…
Phase: PHASE2 • Sponsor: Douglas Johnson • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC